Search

everythinglearnresearchcommunity

for

Search:↓

Topical metformin effectively treats melasma with minimal side effects.

Budesonide and N-acetylcysteine reduced tumors and alopecia in mice, regardless of FHIT gene status.

Continued ritlecitinib treatment can improve hair regrowth in some alopecia areata patients who initially don't respond.

Finasteride reduces melanin production, possibly treating hyperpigmentation and melanoma, but needs more safety research.

Keratinocytes can reduce the survival of certain melanoma cells, suggesting new therapy paths.

A new drug, abrocitinib, helped a child with severe hair loss regrow hair.

Metatrials could improve clinical research in nephrology by speeding up data collection and overcoming challenges like patient recruitment.

The MDR1 C3435T polymorphism does not significantly affect methotrexate response in rheumatoid arthritis patients.

Arsenic trioxide effectively treats relapsed acute promyelocytic leukemia with manageable side effects.

JAK inhibitors improve hair growth in alopecia areata, especially in patchy types.

mTORC1 activity is important for hair growth and color, and targeting it could help treat hair loss and greying.

Machine learning can predict how well patients with alopecia areata will respond to certain treatments.

Stopping methotrexate might reverse lymphoma-like conditions in some patients.

New strategies like vitamin A and dextromethorphan can help reduce methotrexate side effects and improve patient adherence.

Baricitinib treatment can help regrow scalp hair and eyebrows or eyelashes in people with severe alopecia areata.

Suppressing ODC activity reduces tumor growth in hair follicles.

Oral tofacitinib can treat both psoriasis and alopecia universalis by normalizing inflammatory pathways.

Small molecules KY19382 and KY19334 may help treat skin cancer by reducing CDK1 levels and blocking harmful cell signals.

Entospletinib effectively prevents eye and skin GVHD in mice.

Experts agree on how to manage sugar levels and skin reactions in patients taking the cancer drug alpelisib.

Most patients experienced mild to moderate skin problems during a trial for a desmoid tumor treatment.

Tofacitinib can help hair grow back in alopecia patients but hair loss might return if the dose is lowered.

Sporadic trichoblastic neoplasms generally don't recur or spread, with one case showing a specific genetic fusion.

Docetaxel slightly extends prostate cancer survival but has significant side effects and high cost.

Upadacitinib effectively treated a patient with multiple inflammatory conditions.

EGFR cancer drugs often cause a rash, which can lead to distress and isolation, but may also improve outcomes for some cancer patients. Current treatments for the rash are limited, but a compound called menadione shows promise.

The model successfully predicted new uses for existing drugs, like using certain hormonal and heart medications for respiratory and Parkinson's diseases, and a cancer drug for diabetes.

Safflower extract increases melanin production in certain skin cells without harming them.

Baricitinib improved nail condition and hair regrowth in a patient with alopecia and nail abnormalities.